Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)
Bicara Therapeutics (BCAX) recorded Research & Development of $45.77 million in Q2 2026, up 84.6% from $24.8 million a year earlier but down 3.6% from the prior quarter.
Powered by 
Analysis
Bicara Therapeutics (BCAX) Research & Development (2023 - 2026) Analysis & Trends
On a TTM basis, Bicara Therapeutics' Research & Development came in at $159.27 million as of Jun 30, 2026, up 67.8% year-over-year; for FY2025, it was $125.1 million, up 96.7% from FY2024.
- Across earlier years, Research & Development came in at $63.6 million in FY2024 (+107.8%) and $30.6 million in FY2023.
- Quarterly Research & Development has ranged from $6.9 million in Q3 2023 to $47.5 million in Q1 2026 over the past five years.
- On a year-over-year basis, Research & Development has increased for eight consecutive quarters, with growth averaging 94.9% over the last eight quarters.
- Over the past five years, the year-over-year growth in Research & Development ranged from 38.5% (Q1 2026) to 185.8% (Q1 2025).
- Per Business Quant, the preceding three quarters came in at $47.5 million (Q1 2026), $33 million (Q4 2025) and $33 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Bicara Therapeutics | 1.22 Bn | -522.04 Mn | - | 45.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.77 Mn |
| Mar 31, 2026 | 47.50 Mn |
| Dec 31, 2025 | 33.00 Mn |
| Sep 30, 2025 | 33.00 Mn |
| Jun 30, 2025 | 24.80 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Dec 31, 2024 | 19.90 Mn |
| Sep 30, 2024 | 15.90 Mn |
| Jun 30, 2024 | 15.80 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 10.50 Mn |
| Sep 30, 2023 | 6.90 Mn |
API Access
Bicara Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=BCAX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "BCAX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=BCAX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();